- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01266577
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
Background:
- Magnetic resonance imaging (MRI) is a widely used scanning technique to obtain images of the human body and evaluate activity in the brain. A particular MRI method called magnetic resonance spectroscopy (MRS) can be used to study brain chemistry as well, which may help researchers who are studying new treatments for psychiatric illnesses. Researchers are interested in improving current MRI and MRS techniques, as well as developing new MRI and MRS techniques to view and measure brain chemicals and brain activity.
Objectives:
- To implement, develop, and optimize brain chemistry imaging techniques using magnetic resonance imaging and magnetic resonance spectroscopy.
Eligibility:
- Healthy individuals between 18 and 65 years of age.
Design:
- This study will involve a screening visit and a scanning visit at the National Institutes of Health Clinical Center.
- Participants will be screened with a full medical and physical examination, blood and urine tests, and neurological testing.
- During the second visit, participants will have an MRI scan of the brain. (Participants who have received an MRI within the past year will not need to have a second one; the images of the previous scan will be used for this study.) All participants will then have an MRS scan using the same scanning equipment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Magnetic resonance spectroscopy (MRS) is identical to MRI except that the metabolite signal, rather than the dominant water signal, is measured. Proton (1H) MRS and phosphorous (P) MRS are two powerful spectroscopy methods to measure metabolism in vivo.
By using water suppression techniques, proton MRS can monitor levels of important brain metabolites and neurotransmitters such as N-acetylaspartate (NAA), creatine, choline, lactate, myo-inositol, glutamate, glutamine, gamma aminobutyric acid (GABA), and glutathione.
P MRS can be utilized to measure energy phosphate metabolites of inorganic phosphate (Pi), phosphocreatine (PCr), adenosine diphosphate (ADP), and adenosine triphosphate (ATP) in brain and muscle. In addition, phosphocholine (PC), phosphoethanolamine (PE), glycerophosphocholine (GPC) and glyceophosphoethanolamine (GPE) can also be detected in brain tissues.<TAB>
This protocol proposes three main goals. First, to implement and optimize current proton and P MRS methods published in the literature for the imaging of metabolites in human brain and muscle. Second, to further develop new methods for use in similar brain and muscle MRS applications. Third, to exchange MRS data with other studies in order to provide data analysis and quality control for the studies under this, other NIH, or outside protocols.
To develop and optimize in vivo MRS methods, 300 healthy volunteers will be recruited over a period of ten years. The subjects will be aged 18-65 years, and include representative numbers of males, females, and minorities.
The experiments will be performed on the GE 3T, Siemens 3T and 7T MRI scanners located at the NIH In Vivo NMR Research Center. In the first portion of the study, a clinical MRI will be performed to ensure the subject has no abnormal brain conditions. In the second portion of the study, MRS scans will be performed in various system and pulse parameter combinations. No medications will be involved. Total scan time during the MRS scan will be one to two hours long.
We expect to obtain high quality proton and/or phosphorous spectroscopy imaging from healthy volunteers that will help establish accurate and reliable spectroscopy methods for clinical investigators to perform non-invasive studies of psychiatric, neurological disorders, and other diseases in human brain or muscle.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Li An, Ph.D.
- Phone Number: (301) 896-2882
- Email: anl@mail.nih.gov
Study Contact Backup
- Name: Christopher S Johnson
- Phone Number: (301) 402-6695
- Email: johnsonchri@mail.nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- INCLUSION CRITERIA:
- 18-65 years of age
- able to give written informed consent
- healthy based on medical history and physical exam
- enrolled in Protocol 01-M-0254 or Protocol 17-M-0181
EXCLUSION CRITERIA:
- Any current Axis 1 diagnosis
- Clinically significant laboratory abnormalities
- Positive HIV test
- Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
- History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson s disease, seizure disorder or traumatic brain injury
- Inability to lie flat on camera bed for about two and a half hours
- Pregnant or breastfeeding
- Current substance use disorder based on DSM-5
- NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: One Arm
Subjects receive the same scan
|
The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy
Used to perform proton imaging and spectroscopy in the human heads.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The primary outcome is the quality of the MR spectroscopy which includes spectrum signal-to-noise (SNR) ratio, spectral lineshape, linewidth, and resolution.
Time Frame: prospective and ongoing
|
to obtain more accurate and reliable MRS data from the human brain and muscle
|
prospective and ongoing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The secondary outcome is the performance improvements of the scanner hardware, software and methodology.
Time Frame: prospective and ongoing
|
to obtain more accurate and reliable MRS data from the human brain and muscle
|
prospective and ongoing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Li An, Ph.D., National Institute of Mental Health (NIMH)
Publications and helpful links
General Publications
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 110045
- 11-M-0045
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
University Magna GraeciaNot yet recruitingHealthy Volunteer | Healthy Volunteer StudyItaly
-
AbbVieRecruiting
-
AbbVieNot yet recruiting
-
Advenchen Laboratories Nanjing Ltd.Not yet recruitingHealthy VolunteerChina
-
Hinge BioRecruiting
-
HK inno.N CorporationNot yet recruitingHealthy VolunteerSouth Korea
-
AbbVieRecruitingHealthy VolunteerUnited States
-
Mirador Therapeutics, Inc.Recruiting
-
AbbVieRecruitingHealthy VolunteerUnited States
-
Protagonist Therapeutics, Inc.RecruitingHealthy VolunteerAustralia
Clinical Trials on NSR MAGNETOM 7T
-
Medical University of ViennaActive, not recruitingPompe Disease | McArdle DiseaseAustria
-
Sensydia CorporationRecruiting
-
Rennes University HospitalCompletedHealthy VolunteersFrance
-
Hadassah Medical OrganizationUnknownStroke | Myasthenia Gravis | Anosognosia | Acute Inflammatory Demyelinating Polyradiculoneuropathy | AsomatognosiaIsrael
-
Sensydia CorporationUniversity of Pittsburgh Medical CenterCompleted
-
University Hospital, Clermont-FerrandCompletedParkinson's DiseaseFrance
-
Assistance Publique Hopitaux De MarseilleRecruitingNarcolepsy Type 1France
-
Chinese PLA General HospitalRecruiting
-
University of Missouri-ColumbiaSiemens Medical SolutionsRecruitingSmall-cell Lung Cancer | Brain MetastasesUnited States
-
Poitiers University HospitalRecruitingPost-Concussion SyndromeFrance